Andrew Peter O'Brien
Algemeen Directeur bij Grannus Securities Pty Ltd.
Profiel
Andrew Peter O'Brien is currently the Managing Director at Grannus Securities Pty Ltd.
He previously worked as the Chief Executive Officer at BioDiem Ltd., a Non-Executive Director at Nexvet Australia Pty Ltd., a Director at Heart Metabolics Ltd., and a Non-Executive Director at Snap Network Surveillance Pty Ltd.
He also worked as a Vice President at Deutsche Bank AG and an Associate at Morgan Stanley Australia Ltd.
Dr. O'Brien holds an MBA from the University of Melbourne.
Actieve functies van Andrew Peter O'Brien
Bedrijven | Functie | Begin |
---|---|---|
Grannus Securities Pty Ltd. | Algemeen Directeur | - |
Eerdere bekende functies van Andrew Peter O'Brien
Bedrijven | Functie | Einde |
---|---|---|
BioDiem Ltd.
BioDiem Ltd. Pharmaceuticals: MajorHealth Technology BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia. | President | 05-02-2009 |
DEUTSCHE BANK AG | Corporate Officer/Principal | - |
Morgan Stanley Australia Ltd.
Morgan Stanley Australia Ltd. Investment Banks/BrokersFinance Morgan Stanley Australia Ltd. is an Australian broker/dealer subsidiary of Morgan Stanley International, Inc., itself owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in Sydney, the firm offers sales, trading and market-making investment management services to global institutions, hedge funds and industry innovators. | Corporate Officer/Principal | - |
Nexvet Australia Pty Ltd.
Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Directeur/Bestuurslid | - |
Snap Network Surveillance Pty Ltd.
Snap Network Surveillance Pty Ltd. Packaged SoftwareTechnology Services Snap Network Surveillance Pty Ltd. engages in the provision of video surveillance control software. It offers Snap FMX software that allows customers to take control of large-scale IP video surveillance networks. The company was founded by Anton van den Hengel and Henry Detmold and is headquartered in Adelaide, Australia. | Directeur/Bestuurslid | - |
Opleiding van Andrew Peter O'Brien
University of Melbourne | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
DEUTSCHE BANK AG | Finance |
Bedrijven in privébezit | 6 |
---|---|
BioDiem Ltd.
BioDiem Ltd. Pharmaceuticals: MajorHealth Technology BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia. | Health Technology |
Heart Metabolics Ltd.
Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
Snap Network Surveillance Pty Ltd.
Snap Network Surveillance Pty Ltd. Packaged SoftwareTechnology Services Snap Network Surveillance Pty Ltd. engages in the provision of video surveillance control software. It offers Snap FMX software that allows customers to take control of large-scale IP video surveillance networks. The company was founded by Anton van den Hengel and Henry Detmold and is headquartered in Adelaide, Australia. | Technology Services |
Nexvet Australia Pty Ltd.
Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Grannus Securities Pty Ltd. | |
Morgan Stanley Australia Ltd.
Morgan Stanley Australia Ltd. Investment Banks/BrokersFinance Morgan Stanley Australia Ltd. is an Australian broker/dealer subsidiary of Morgan Stanley International, Inc., itself owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in Sydney, the firm offers sales, trading and market-making investment management services to global institutions, hedge funds and industry innovators. | Finance |